Ribas, A., Svane, I. M., Ascierto, P. A., Atkinson, V., Ghori, R., Giacomo, A. M. D., . . . Croydon, E. S. (2020). KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. BMJ Publishing Group.
Chicago Style (17th ed.) CitationRibas, Antoni, et al. KEYNOTE-022 Part 3: A Randomized, Double-blind, Phase 2 Study of Pembrolizumab, Dabrafenib, and Trametinib in BRAF-mutant Melanoma. BMJ Publishing Group, 2020.
MLA (8th ed.) CitationRibas, Antoni, et al. KEYNOTE-022 Part 3: A Randomized, Double-blind, Phase 2 Study of Pembrolizumab, Dabrafenib, and Trametinib in BRAF-mutant Melanoma. BMJ Publishing Group, 2020.
Warning: These citations may not always be 100% accurate.